Affiliation:
1. Department of Immunology, College of Basic Medical Science Dalian Medical University Dalian Liaoning China
2. Department of Rheumatology The First Affiliated Hospital of Nanjing Medical University Nanjing Jiangsu China
3. Department of Flow Cytometry Center The Second Hospital of Dalian Medical University Dalian Liaoning China
Abstract
AbstractBackgroundRheumatoid arthritis (RA) is an autoimmune disease characterized by destructive polyarthritis, and abnormal T–B‐cell interactions may contribute to its pathogenesis. This study aimed to investigate the characteristics and roles of CD4+ programmed death 1 (PD‐1)+Foxp3− T cells in relation to the B‐cell response in patients with RA.MethodsThis study included 155 patients with RA and 36 age‐ and sex‐matched healthy controls (HCs) from the Second Hospital of Dalian Medical University in China. Flow cytometry was used to assess the proportion and properties of peripheral CD4+PD‐1+Foxp3+ T cells, including their proliferation, activation, cytokine production, and capacity to induce B‐cell differentiation.ResultsThe proportion of CD4+PD‐1+Foxp3− T cells was increased in patients with RA compared with HCs ([10.78 ± 0.60]% vs. [5.67 ± 0.40]%, p < 0.001), and this was positively associated with the B‐cell response. Compared with CD4+PD‐1+Foxp3+ T cells, CD4+PD‐1+Foxp3− T cells from patients with RA exhibited increased expression of Ki67 ([6.52 ± 0.41]% vs. [3.87 ± 0.42]%, p < 0.01) and activation markers, produced higher levels of cytokines, and showed enhanced B‐cell differentiation. Furthermore, anti‐interleukin‐6R antagonists decreased the proportion, activation, and cytokine production of CD4+PD‐1+Foxp3− T cells in vitro. The frequency of type 2 CD4+PD‐1+Foxp3− T cells was significantly higher in patients with RA than that in HCs ([37.27 ± 1.43]% vs. [29.05 ± 1.30]%, p < 0.05).ConclusionsPeripherally expanded CD4+PD‐1+Foxp3− T cells in patients with RA, which induced B‐cell hyperactivity, may be inclined toward type 2 helper T cells. Our findings revealed a novel T‐cell subset that contributes to B‐cell hyperactivity in the pathogenesis of RA.
Funder
National Natural Science Foundation of China
Doctoral Start-up Foundation of Liaoning Province